Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Gelderblom

Showing results (11-20 of 488) with videos related to

Pageof 49
Sort By:
Cancer Treatment Reviews|June 19, 2008
Clinical and pharmacogenetic factors associated with irinotecan toxicityDinemarie Kweekel, Henk-Jan Guchelaar, Hans Gelderblom
The Lancet. Oncology|November 30, 2020
COVID-19 and systemic anticancer therapy: exploiting uncertaintyHans Gelderblom, Hendrik Veelken, Anne M Stiggelbout
Current Opinion in Molecular Therapeutics|December 15, 2010
Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bulletJan Pander, Henk Jan Guchelaar, Hans Gelderblom
Drug Discovery Today|December 7, 2007
Pharmacogenetics of EGFR and VEGF inhibitionJan Pander, Hans Gelderblom, Henk-Jan Guchelaar
Drug Discovery Today|October 11, 2011
Liposomal drug formulations in cancer therapy: 15 years along the roadMarije Slingerland, Henk-Jan Guchelaar, Hans Gelderblom
Anti-Cancer Drugs|November 5, 2013
Histone deacetylase inhibitors: an overview of the clinical studies in solid tumorsMarije Slingerland, Henk-Jan Guchelaar, Hans Gelderblom
Best Practice & Research. Clinical Gastroenterology|May 6, 2009
Pharmacogenetics in chemotherapy of colorectal cancerLieke Henriette Tanja, Henk-Jan Guchelaar, Hans Gelderblom
Annals of Surgical Oncology|November 15, 2006
Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developmentsNeeltje Steeghs, Johan W R Nortier, Hans Gelderblom
Current Treatment Options in Oncology|June 5, 2012
New systemic therapy options for advanced sarcomasWinette T A van der Graaf, Hans Gelderblom
Cancer Treatment Reviews|January 10, 2012
Phenotyping drug disposition in oncologyFrans L Opdam, Hans Gelderblom, Henk-Jan Guchelaar
Pageof 49

Showing results (11-20 of 488) with videos related to

Sort By:
Pageof 49
Cancer Treatment Reviews|June 19, 2008
Clinical and pharmacogenetic factors associated with irinotecan toxicityDinemarie Kweekel, Henk-Jan Guchelaar, Hans Gelderblom
The Lancet. Oncology|November 30, 2020
COVID-19 and systemic anticancer therapy: exploiting uncertaintyHans Gelderblom, Hendrik Veelken, Anne M Stiggelbout
Current Opinion in Molecular Therapeutics|December 15, 2010
Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bulletJan Pander, Henk Jan Guchelaar, Hans Gelderblom
Drug Discovery Today|December 7, 2007
Pharmacogenetics of EGFR and VEGF inhibitionJan Pander, Hans Gelderblom, Henk-Jan Guchelaar
Drug Discovery Today|October 11, 2011
Liposomal drug formulations in cancer therapy: 15 years along the roadMarije Slingerland, Henk-Jan Guchelaar, Hans Gelderblom
Anti-Cancer Drugs|November 5, 2013
Histone deacetylase inhibitors: an overview of the clinical studies in solid tumorsMarije Slingerland, Henk-Jan Guchelaar, Hans Gelderblom
Best Practice & Research. Clinical Gastroenterology|May 6, 2009
Pharmacogenetics in chemotherapy of colorectal cancerLieke Henriette Tanja, Henk-Jan Guchelaar, Hans Gelderblom
Annals of Surgical Oncology|November 15, 2006
Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developmentsNeeltje Steeghs, Johan W R Nortier, Hans Gelderblom
Current Treatment Options in Oncology|June 5, 2012
New systemic therapy options for advanced sarcomasWinette T A van der Graaf, Hans Gelderblom
Cancer Treatment Reviews|January 10, 2012
Phenotyping drug disposition in oncologyFrans L Opdam, Hans Gelderblom, Henk-Jan Guchelaar
Pageof 49